Yan Zhen, Gao Wen-Cang, Wang Xiao-Xiao, Xu Hong-Quan, Li Qian, Chen Jian-Xiang, Pang De-Xiang, Xie Tian
First Clinical Medical Institute, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, 210023, China.
Department of Traditional Chinese Medicine, Integrated Chinese and Western Medicine, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, Zhejiang, 310000, China.
Heliyon. 2024 Aug 31;10(18):e37292. doi: 10.1016/j.heliyon.2024.e37292. eCollection 2024 Sep 30.
This study involved evaluating the efficacy of the Feijinsheng formula in the therapeutic management of patients with advanced non-small cell lung cancer (NSCLC).
We extracted the medical records of patients with advanced NSCLC undergoing treatment in the oncology department at the Second Affiliated Hospital of Zhejiang Chinese Medicine University from the medical record system. After applying inclusion and exclusion criteria, clinical data of 150 patients were collected. The patients were stratified into two groups based on their usage of the Feijinsheng formula, comprising 69 cases in the Exposed group and 81 cases in the Control group. A comparative analysis of the survival time difference between the two groups was conducted.
The data between the two groups exhibited similarity ( > 0.05). Following treatment, the Exposed group demonstrated a notably prolonged overall survival time compared to the Control group ( < 0.05). While the Exposed group displayed a higher objective remission rate than the Control group, this disparity did not reach statistical significance ( > 0.05).
The Feijinsheng formula extended the duration of survival of patients with advanced NSCLC.
本研究旨在评估肺金生方对晚期非小细胞肺癌(NSCLC)患者的治疗效果。
我们从浙江中医药大学附属第二医院肿瘤科的病历系统中提取了接受治疗的晚期NSCLC患者的病历。在应用纳入和排除标准后,收集了150例患者的临床数据。根据肺金生方的使用情况,将患者分为两组,暴露组69例,对照组81例。对两组之间的生存时间差异进行了比较分析。
两组数据具有相似性(>0.05)。治疗后,暴露组的总生存时间明显长于对照组(<0.05)。虽然暴露组的客观缓解率高于对照组,但这种差异未达到统计学意义(>0.05)。
肺金生方延长了晚期NSCLC患者的生存时间。